SCHEMBL19436643

SCHEMBL19436643

CCOC(=O)c1cnn2c(COC)cc(-c3cccc(OC)c3)nc12

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 10/20 0.59
HPGD P15428 9/20 0.59
KDM4E B2RXH2 9/20 0.59
HSD17B10 Q99714 8/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
NPC1 O15118 2/20 0.59
RAB9A P51151 2/20 0.59
CSNK1D P48730 3/20 0.56
CASP1 P29466 4/20 0.55
CASP7 P55210 3/20 0.55
TSHR P16473 2/20 0.55
THRB P10828 3/20 0.54
MAPT P10636 5/20 0.48
TP53 P04637 2/20 0.47
GAA P10253 2/20 0.47
GLA P06280 1/20 0.47
NPSR1 Q6W5P4 2/20 0.44
FOS P01100 1/20 0.43
JUN P05412 1/20 0.43
NFKB1 P19838 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19436667 0.89 HSD17B10 (0.68) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL19436708 0.89 KDM4E (0.60) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL29929061 0.89 KDM4E (0.60) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL19436687 0.88 ALDH1A1 (0.77) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL19436738 0.88 HSD17B10 (0.67) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL19436735 0.88 HSD17B10 (0.67) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL29929434 0.88 ALDH1A1 (0.77) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL19436737 0.86 HSD17B10 (0.56) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL19436765 0.83 ALDH1A1 (0.76) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2
SCHEMBL19436694 0.83 CSNK1D (0.56) ALDH1A1HPGDKDM4EHSD17B10SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators Bial—R&D Investments, S.A. (PT) 2024-10-15 US disclosed
US-20230098494-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. 2023-03-30 US disclosed
US-11192892-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders Bial—R&D Investments, S.A. (PT) 2021-12-07 US disclosed
US-10934298-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders BIAL—BioTech Investments, Inc. (PT) 2021-03-02 US disclosed
US-20190330213-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2019-10-31 US disclosed
EP-3440080-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS Lysosomal Therapeutics Inc. (US) 2019-02-13 EP disclosed
US-9840510-B1 Pyrazolo[1,5-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders LYSOSOMAL THERAPEUTICS INC. (US) 2017-12-12 US disclosed
US-20170349598-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL - R&D INVESTMENTS, S.A. (PT) 2017-12-07 US disclosed
WO-2017176960-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS LYSOSOMAL THERAPEUTICS INC. (US) 2017-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12116369-B2 Substituted pyrazolo[1,5-a]pyrimidines as glucocerebrosidase activators GBA1, GALC, GBA3 ALDH1A1 1260/4885HPGD 2491/4885KDM4E 1067/4885
US-11192892-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders GBA1, PARK7, GAA ALDH1A1 1084/4885HPGD 1253/4885KDM4E 889/4885
US-20170349598-A1 PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 ALDH1A1 1104/4885HPGD 1842/4885KDM4E 690/4885
US-20230098494-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 ALDH1A1 1104/4885HPGD 1842/4885KDM4E 690/4885
US-10934298-B2 Substituted pyrazolo[1,5-a]pyrimidines for the treatment of medical disorders GBA1, GAA, PARK7 ALDH1A1 840/4885HPGD 1492/4885KDM4E 1447/4885
US-20190330213-A1 PYRAZOLO[1,5-a]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS GBA1, GAA, PARK7 ALDH1A1 1104/4885HPGD 1842/4885KDM4E 690/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.